Shots: The US FDA has approved FoundationOne CDx to be used as a CDx for Alunbrig (brigatinib) which is approved for the treatment of adult patients with ALK+ mNSCLC as […]readmore
Tags : FoundationOne CDx
Shots: The US FDA approved FoundationOneCDx to be used as a CDx for Vitrakvi (larotrectinib) to identify patients with NTRK fusions across all solid tumors. The genomic test is currently […]readmore
Shots: The MHLW has approved the expanded use of FoundationOne CDx for Rozlytrek to treat ROS1 fusion-positive, LA/ m-NSCLC, allowing the physician to identify NSCLC patients who could benefit from […]readmore
Shots: The US FDA approved FoundationOne CDx as a CDx for Lynparza (co-developed & co-commercialized by Merck & AstraZeneca) for 1L maintenance therapy in BRCA-mutated advanced ovarian cancer The test […]readmore